Cytokinetics Inc.
280 East Grand Avenue
South San Francisco,
CA 94080
United States - Map
Phone: 650-624-3000
Fax: 650-624-3010
Web Site: http://www.cytokinetics.com
| Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The companys lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The companys products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295. The company was founded in 1997 and is headquartered in South San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. James H. Sabry M.D., Ph.D., 50
Co-Founder, Chairman, Chairman of Scientific Advisory Board and Consultant |
$
40.00K |
$
277.00K | Mr. Robert I. Blum , 45
Chief Exec. Officer, Pres, Director and Chief Exec. of the Biopharmaceutical Concern |
$
436.00K |
$
116.00K | Dr. James A. Spudich Ph.D., 67
Co-Founder, Independent Director, Member of the Scientific Advisory Board and Member of Nominating & Governance Committee |
$
25.00K | N/A | Ms. Sharon Surrey-Barbari , 54
Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. and Sec. |
$
345.00K |
$
0 | Dr. David J. Morgans Jr., Ph.D., 56
Exec. VP of Preclinical R&D |
$
349.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.06 (1.76%) 
Profile
